Acquisition of immunosurveillance and immunoevasion concepts, knowledge of the biological basis of the most tumor escape mechanisms, understanding of the biological rational understanding of the most used approaches for the modulation of the immune response with anti-cancer purposes.
Specific knowledge on the relationship between the host's immune system and the tumor and the main anti-tumor approaches based on immunomodulatory strategies.
The immune system in the tumor microenvironment: Inflammation in tumor progression; Functional role of tumor-associated leukocytes and other host cells; Immune infiltrate and tumor angiogenesis; Effects of the tumor on local and systemic immune regulation; Tumor-associated regulatory T cells; Tumor-associated suppressor cells of the myeloid lineage (MDSC, TAM, TAN); Tertiary lymphoid structures in the tumor; Therapeutic approaches targeting the tumor microenvironment.
Cancer immunology and immunotherapy in solid tumors: History and principles of immune cancer treatment; Predictors of response to immune therapies; Development of anticancer immune agents; Evidence of efficacy of immune therapies; Immunotherapies in different models of solid cancers; T-cell therapies; Cancer vaccines; Future trends in cancer immune therapy; Toxicity of cancer immune therapies; Sustainability of anticancer agents.
Cancer immunology and immunotherapy in hematological tumors: The role of checkpoint inhibitors in Lymphomas; Adoptive immunotherapy for cancer (CAR T cells); Allogenic hematopoietic stem cell transplantation as adoptive immunotherapy in cancer; The targeting of cancer microenvironment (T-reg, MDSC, NK, Dendritic, macrophages): the paradigma of multiple myeloma; The role of the B-cell receptor signaling in lymphoid malignancies.